SCHEMBL3008917

SCHEMBL3008917

COc1ccc(Cl)cc1S(=O)(=O)N1CCN(c2nc(Cc3ccc(Cl)c(Cl)c3)cs2)CC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.51
LMNA P02545 4/20 0.51
ALDH1A1 P00352 2/20 0.51
KDM4E B2RXH2 1/20 0.51
POLB P06746 1/20 0.51
HPGD P15428 1/20 0.51
RAB9A P51151 1/20 0.51
TSHR P16473 1/20 0.51
CYP3A4 P08684 2/20 0.49
CYP2C19 P33261 2/20 0.49
SMN1; SMN2 Q16637 1/20 0.47
TP53 P04637 1/20 0.46
ALOX12 P18054 1/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
CYP2C9 P11712 1/20 0.44
GAA P10253 1/20 0.44
HTT P42858 1/20 0.44
MAPK1 P28482 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3651939 0.95 MAPT (0.48) MAPTLMNAALDH1A1KDM4EPOLB
SCHEMBL3007463 0.94 ALDH1A1 (0.52) MAPTLMNAALDH1A1KDM4EPOLB
SCHEMBL3015393 0.94 ALDH1A1 (0.54) MAPTLMNAALDH1A1KDM4EPOLB
SCHEMBL3006923 0.93 LMNA (0.54) MAPTLMNAALDH1A1KDM4EPOLB
SCHEMBL3002880 0.92 LMNA (0.53) MAPTLMNAALDH1A1KDM4EPOLB
SCHEMBL3014635 0.92 ALDH1A1 (0.51) MAPTLMNAALDH1A1KDM4EHPGD
SCHEMBL3002720 0.91 LMNA (0.54) MAPTLMNAALDH1A1KDM4EPOLB
SCHEMBL3020197 0.91 MAPT (0.51) MAPTLMNAALDH1A1KDM4EPOLB
SCHEMBL3007202 0.91 GAA (0.49) MAPTLMNAALDH1A1KDM4EPOLB
SCHEMBL3013689 0.91 LMNA (0.51) MAPTLMNAALDH1A1KDM4EPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MAPT 18/4885LMNA 80/4885ALDH1A1 3510/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.